drugset / Trial / NCT02531815
Dose Escalation Study of PF-06741086 In Healthy Subjects
RandomizedTriple-blindBasic science
Summary
This Phase 1 first-in-human single ascending dose study will be a randomized, double-blind, placebo-controlled investigation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06741086.
Timeline
- Start
- 2015-08
- Primary completion
- 2016-07
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Marstacimab | Monoclonal antibody | 30 mg | Subcutaneous |
Indications
No indication recorded.